This prospective single-center randomized controlled trial aims at evaluating the safety and feasibility of an hemoadsorption protocol using Jafron HA-60 during cardio-pulmonary bypass in 20 pediatric patients undergoing open-heart surgery.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Screened-to-enrolled patients' ratio and number of intervention delivery group
Timeframe: Start CPB, End CPB, 1 Day and aftrer 28 day
Device-related adverse events
Timeframe: From beginning of cardiopulmonary bypass to 7 days after ICU admission or ICU discharge wichever occurs first.